Protective effect of N^G-monomethyl-L-arginine against hypotension inducted by combined tumour necrosis factor-α and whole body hyperthermia in rats

References

• Aisaka K., Gross S. S., Griffith O. W., Levi R. NG-methylarginine, an inhibitor of endothelium-derived nitrix oxide synthesis, is a potent pressor agent in the guinea pig:Does nitric oxide regular blood pressure in vivo. Biochemical and Biophysical Research Communications 1988; 160: 881–886
   Google Scholar
• Baba H., Stephens L. C., Strebel F. R., Siddick Z. H., Newman R. A., Ohno S., Bull J. M. C. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia. Cancer Research 1991; 51: 3568–3577
   PubMed Web of Science ®Google Scholar
• Billiar T. R., Curran R. D., Harbrecht B. G., Stuehr D. J., Demetris A. J., Simmons R. L. Modulation of nitrix oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrite/nitrate biosynthesis while promoting hepatic damage. Journal of Leukocyte Biology 1990; 48: 565–569
   PubMed Web of Science ®Google Scholar
• Bull J. M., Lees D., Schuette W., Schuette W., Whang-Peng J., Smith R., Bynum G., Atkins R., Gotdiener J. S., Gralnick H. R., Shawker T. H., DeLvita V. T. Whole body hyperthermia: a phase-I trial of a potential adjuvant to chemotherapy. Annals of Internal Medicine 1979; 90: 317–323
   PubMed Web of Science ®Google Scholar
• Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proceedings of the National Academy Science of USA 1975; 72: 3666–3670
   PubMed Web of Science ®Google Scholar
• Creaven P. J., Plager J. E., Dupree S., Huben R. P., Takita H., Mittelman A., Proefrock A. Phase I clinical trial of recombinant human tumour necrosis factor. Cancer Chemotherapy Pharmacology 1987; 20: 137–144
   PubMed Web of Science ®Google Scholar
• Eddy H. A. Alteration in tumor microvasculature during hyperthermia. Radiology 1980; 137: 515–521
   PubMed Web of Science ®Google Scholar
• Hauser G. J., McIntosh J. K., Travis W. D., Rosenberg S. A. Manipulation of oxygen radical-scavenging capacity in mice laters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy. Cancer Research 1990; 50: 3503–3508
   PubMed Web of Science ®Google Scholar
• Hibbs J. B., Taintor R. R., Vavrin Z., Rachlin E. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochemical and Biophysical Research Communications 1988; 157: 87–94
   PubMed Web of Science ®Google Scholar
• Kallinowski F., Schaefer C., Tyler G., Vaupel P. In vivo targets of recombinant human tumour necrosis factor-α: blood flow, oxygen consumption and growth of isotransplanted rat tumours. British Journal of Cancer 1989; 60: 555–560
   PubMed Web of Science ®Google Scholar
• Kettelhut I. C., Fiers W., Goldberg A. L. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proceedings of the National Academy Science of USA 1987; 84: 4273–4277
   PubMedGoogle Scholar
• Khokhar A. R., Lumetta G., Doran S. L. A convenient method for the preparation of anti-tumour carboxylato (l,2-diaminocyclohexane)-platinum (II) complexes. Inorganica Chimica Acta 1988; 151: 87–88
   Web of Science ®Google Scholar
• Kilbourn R. G., Gross S. S., Jubran A., Adamus J., Griffith O. W., Levi R., Lodato R. F. NG-Methyl-L-arginine inhibits tumor necrosis factor-induced hypotension:Implications for the involvement of nitric oxide. Proceedings of the National Academy Science of USA 1990a; 87: 3629–3632
   PubMed Web of Science ®Google Scholar
• Kilbourn R. G., Jubran A., Gross S. S., Griffin O. W., Levi R., Adams J., Lodato R. F. Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochemical and Biophysical Research Communications 1990b; 172: 1132–1138
   PubMed Web of Science ®Google Scholar
• Kilbourn R. G., Griffith O. W. Overproduction of nitric oxide in cytokine-mediated and septic shock. Journal of National Cancer Institute 1992a; 84: 827–831
   PubMed Web of Science ®Google Scholar
• Kilbourn R. G., Gross S. S., Lodato R. F., Adams J., Levi R., Miller L. L., Lachman L. B., Griffith O. W. Inhibition of interleukin-1 α-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1α-induced hypotension by Nw-amino-L-arginine. Journal of National Cancer Institute 1992b; 84: 1008–1016
   PubMed Web of Science ®Google Scholar
• Kim Y. D., Lake C. R., Lees D. E., Schuette W. H., Bull J. M., Weise V., Kopin I. Hemodynamic and plasma catecholamine responses to hyperthermic cancer therapy in humans. American Journal of Physiology 1979; 237: H570–H574
   PubMedGoogle Scholar
• Larkin J. M., Edwards W. S., Smith D. E., Clarke P. J. Systemic thermotherapy: Description of a method and physiologic tolerance in clinical subjects. Cancer 1977; 40: 3155–3159
   PubMed Web of Science ®Google Scholar
• Li L., Kilbourn R. G., Adams J., Fildler I. J. Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Research 1991; 51: 2531–2535
   PubMed Web of Science ®Google Scholar
• Lodato R. F. Decreased O2 consumption and cardiac output during normobaric hyperoxia in conscious dogs. Journal of Applied Physiology 1989; 67: 1551–1559
   PubMed Web of Science ®Google Scholar
• Maeta M., Koga S., Shimizu N., Kanayama H., Hamazoe R., Karino T., Yamane T., Oda M. Effect of extracorporeally induced total body hyperthermia for cancer on cardiovascular function. Japanese Heart Journal 1984; 25: 993–1000
   PubMedGoogle Scholar
• Malik S., Balkwill F. R. Antiproliferative and antitumor activity of TNF in vitro and in vivo. Tumor Necrosis Factors 1992, B. B. Aggarwal, K. H. Vilce. Marcel Dekker, New York 1992; 239–268
   Google Scholar
• Nava E., Palmer R. M., Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial. Lancet 1991; 338: 1555–1557
   PubMed Web of Science ®Google Scholar
• Ohno S., Siddik Z. H., Strebel F. R., Stephans L. C., Siddik Z. H., Klostergaard J., Tomasovic S. P., Khokhar A. R., Bull J. M. C. Increased therapeutic efficacy induced by tumor necrosis factor α combined with platinum complexes and whole body hyperthermia in rats. Cancer Research 1992; 52: 4096–4101
   PubMed Web of Science ®Google Scholar
• Page R. L., Meyer R. E., Thrall D. E., Dewhirst M. W. Cardiovascular and metabolic response of tumour-bearing dogs to whole body hyperthermia. International Journal of Hyperthermia 1987; 6: 513–525
   Google Scholar
• Palmer R. M. J., Ferrige A. G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524–526
   PubMed Web of Science ®Google Scholar
• Palmer R. M. J., Rees D. D., Ashton D. S., Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochemical and Biophysical Research Communications 1988; 153: 1251–1256
   PubMed Web of Science ®Google Scholar
• Petros A., Bennett D., Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338: 1557–1558
   PubMed Web of Science ®Google Scholar
• Rees D. D., Palmer R. M. J., Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proceedings of the National Academy Science of USA 1989; 86: 3375–3378
   PubMed Web of Science ®Google Scholar
• Rothstein J. L., Schreiber H. Tissue damage caused by TNF and complement. Tomor Necrosis Factors, 1992, B. B. Aggarwal, K. J. Vilce. Marcel Dekker, Inc, New York 1988; 453–481
   Google Scholar
• Schirmer W. J., Schirmer J. M., Fry D. E. Recombinant human tumor necrosis factor produced hemodynamic changes characteristic of sepsis and endotoxemia. Archives of Surgery 1989; 124: 445–448
   PubMedGoogle Scholar
• Stricker E. M. Evaporative cooling in the rat: Interaction with heat loss from the tail. Quarterly Journal of Experimental Physiology 1971; 56: 231–241
   PubMedGoogle Scholar
• Tracy K. J., Beutler B., Lowry S. F., Merryweather J., Wolpe S., Milsark I. W., Hariri R. J., Fahey T. J., Zentella A., Albert J. D., Shires G. T., Cerami A. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 324: 470–474
   Google Scholar
• Tracey K. H., Loery K. H. S. F., Fahey T. J., Albert J. D., Fong Y., Hesse D., Beutler B., Manogue K. R., Calvano S., Wei H., Cerami A., Shires G. T. Cachectin/Tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surgery, Gynecology and Obstetrics 1987; 164: 415–422
   PubMedGoogle Scholar
• Turner C. R., Esser K. M., Wheeldon E. B., Slivjak M., Smith E. F. Cardiovascular and pulmonary effects of human recombinant tumor necrosis factor in the conscious rat. Circulatory Shock 1989; 28: 369–384
   PubMedGoogle Scholar
• Watanabe N., Niitsu Y., Umeno H., Sone H., Neda H., Yamauchi N., Maeda M., Urushizaki I. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Research 1988a; 48: 650–653
   PubMed Web of Science ®Google Scholar
• Watanabe N., Niitsu Y., Umeno H., Kuriyama H., Neda H., Yamauchi N., Maeda M., Urushizaki I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Research 1988b; 48: 2179–2183
   PubMed Web of Science ®Google Scholar
• Wondergem J., Bulger R. E., Strebel F. R., Newman R. A., Travis E. L., Stephans L. C., Bull J. M. C. Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury. Cancer Research 1988a; 48: 440–446
   PubMed Web of Science ®Google Scholar
• Wondergem J., Strebel F. R., Siddik Z. H., Newman R. A., Bull J. M. C. The effects of anaesthetics on cisplatinum-induced toxicity at normal temperatures and during whole-body hyperthermia: the influence of NaCl concentration of the vehicle. International Journal of Hyperthermia 1988b; 4: 643–654
   PubMed Web of Science ®Google Scholar